What is the recommended evaluation and management of Myelodyspastic syndrome?

Myelodysplastic Syndrome: Evaluation and Management

For suspected MDS, obtain a bone marrow aspirate and biopsy with morphology, cytogenetics, flow cytometry, and next-generation sequencing myeloid mutation panel, then risk-stratify using IPSS-R or IPSS-M to guide treatment selection between supportive care/disease-modifying agents for lower-risk disease versus hypomethylating agents or allogeneic transplant for higher-risk disease. 1

Diagnostic Evaluation

Essential Diagnostic Components

The diagnosis requires bone marrow examination demonstrating dysplasia and excluding other causes 1, 2. Specifically obtain:

• Bone marrow aspirate and biopsy with morphologic assessment for dysplasia (uni- or multi-lineage) and blast percentage
• Cytogenetics (essential for diagnosis and prognosis) 1
• Flow cytometry to assess for aberrant immunophenotypes
• Next-generation sequencing myeloid mutation panel 1
• Peripheral blood counts documenting cytopenias

Clinical Context to Assess

Look for specific risk factors and presenting features:

• Age: Median age 77 years; incidence increases dramatically after age 70 (26.9 per 100,000 in ages 70-79,55.4 per 100,000 in ≥80 years) 1
• Prior exposures: Chemotherapy or radiation therapy 3
• Symptoms: Anemia-related fatigue, bleeding from thrombocytopenia, infections from neutropenia 3
• Comorbidities: Critical for treatment selection given advanced patient age 1

Risk Stratification

Use IPSS-R or the newer IPSS-M (which incorporates genomic data) to categorize patients into lower-risk versus higher-risk disease 4. This classification drives all subsequent treatment decisions and prognostic discussions:

• Lower-risk MDS: Median survival 3-10 years 3
• Higher-risk MDS: Median survival <3 years 3

The stratification incorporates peripheral cytopenias, bone marrow blast percentage, cytogenetic characteristics, and (in IPSS-M) mutational profiles 4.

Management Approach

Lower-Risk MDS

The primary goal is improving cytopenias (especially anemia), reducing transfusion burden, and delaying progression 5, 3.

For Isolated Anemia with EPO <500 U/L:

Start with erythropoiesis-stimulating agents (ESAs) such as recombinant erythropoietin or darbepoetin alfa as first-line therapy 6, 5, 3. These achieve:

• 15-40% response rates 3
• Median response duration 8-23 months 3
• Better and more durable responses when initiated before permanent transfusion dependence develops 5

For Specific Disease Subtypes:

Tailor therapy to disease biology 5:

• MDS with ring sideroblasts: Use luspatercept (FDA-approved 2020) 4
• MDS with deletion 5q (low-risk): Use lenalidomide 6, 5
• Hypoplastic MDS without high-risk genetics: Consider immunosuppressive therapy (antithymocyte globulin with cyclosporine in selected cases) 6, 5

ESA Failure or Multiple Cytopenias:

Consider oral low-dose hypomethylating agents or clinical trial enrollment 7.

Thrombocytopenia Management:

• Platelet transfusions are not routinely prophylactic except during myelosuppressive therapy 6
• TPO receptor agonists (romiplostim, eltrombopag) showed efficacy in trials but are not approved in Europe and cannot be recommended outside clinical trials 6
• Should be restricted to patients without excess marrow blasts if used 6

Higher-Risk MDS

The goal is to prolong survival and delay AML transformation 4, 3.

First-Line Therapy:

Hypomethylating agents (azacitidine, decitabine, or oral decitabine/cedazuridine) are the standard of care 5, 4, 3. The oral decitabine/cedazuridine combination was FDA-approved in 2020 4.

Important caveat: Combinations with other drugs as first-line treatment have not proven more efficacious than HMA monotherapy to date, though venetoclax combinations (approved for AML) are under evaluation 5.

Curative Intent:

Allogeneic hematopoietic stem cell transplantation is the only potentially curative therapy and should be considered at diagnosis for all eligible higher-risk patients 3. Key considerations:

• Evaluate early for transplant eligibility, including HLA-matched donor availability 8
• Patients being considered for transplant should receive early iron chelation 6
• Relapse remains the main cause of transplant failure 5
• Outcomes with alloSCT have improved based on 2021 reports 4

HMA Failure:

This represents a major unmet need with dismal outcomes 7. Options include:

• Clinical trial enrollment (strongly preferred) 4, 7
• Experimental agents: venetoclax, CPX-351, immunotherapies, or other novel agents 7
• No approved interventions exist for this population 4

Supportive Care (All Risk Categories)

Transfusion Management:

Maintain hemoglobin threshold of at least 8 g/dL, and 9-10 g/dL in patients with comorbidities or poor functional tolerance 6. Transfuse sufficient RBC units (over 2-3 days if needed) to raise hemoglobin above 10 g/dL 6.

Iron Chelation:

Start chelation in lower-risk MDS patients with favorable prognosis who have received 20-60 RBC concentrates or ferritin >1000-2500 U/L 6. Rationale:

• Heart iron overload occurs after 70-80 RBC concentrates 6
• T2* CMR <20 milliseconds associates with decreased ejection fraction and heart failure risk 6
• TELESTO trial showed improved event-free survival with chelation 6
• Chelate early in potential transplant candidates 6

Infection Management:

• No prophylactic antibiotics or G-CSF for neutropenia 6
• Rapid broad-spectrum antibiotics for fever/infection 6
• Short-term G-CSF during severe infections in neutropenic patients 6

Additional Support:

Offer psychosocial support and patient support group contact 6.

Common Pitfalls

• Delaying ESA initiation: Start before permanent transfusion dependence for better outcomes 5
• Using HMA combinations as first-line: No proven benefit over monotherapy 5
• Neglecting transplant evaluation: Assess eligibility early in higher-risk patients 3
• Inadequate transfusion support: Maintain appropriate hemoglobin thresholds for quality of life 6
• Missing iron chelation candidates: Screen transfusion burden and ferritin levels in lower-risk patients 6